Please use this identifier to cite or link to this item:
Title: Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients
Author: Muñoz Esquerre, Mariana
Ferreiro, José Luis
Huertas, David
Marcano, Ana Lucrecia
López Sánchez, Marta
Roura, Gerard
Gómez Hospital, Joan Antoni
Dorca i Sargatal, Jordi
Cequier Fillat, Àngel R.
Santos Pérez, Salud
Keywords: Inflamació
Agregació plaquetària
Malalties pulmonars obstructives cròniques
Blood platelet aggregation
Chronic obstructive pulmonary diseases
Issue Date: 28-Dec-2017
Publisher: Dove Medical Press
Abstract: Background: a higher risk of atherothrombotic cardiovascular events, which are platelet-driven processes, has been described during acute exacerbations of chronic obstructive pulmonary disease (AECOPD). However, the relevance of platelet reactivity during AECOPD and whether this is affected by antiplatelet agents are not fully elucidated to date. This study aimed to evaluate whether platelet reactivity is augmented during an exacerbation in COPD patients with and without antiplatelet therapy and its association with systemic inflammatory parameters. Materials and methods: prospective, observational, ex vivo investigation was conducted in consecutive patients suffering an exacerbation of COPD. Platelet reactivity was assessed during AECOPD and at stable state. Platelet function assays included: 1) vasodilator-stimulated phosphoprotein assay expressed as P2Y12 reactivity index (PRI), 2) multiple electrode aggregometry and 3) optical aggregometry. Systemic inflammatory parameters such as leukocyte count, interleukin-6 and fibrinogen were also assessed. Results: higher platelet reactivity was observed during AECOPD compared to stability measured by vasodilator-stimulated phosphoprotein (PRI: 75.2%±1.9% vs 68.8%±2.4%, p=0.001). This augmented platelet aggregability was also observed in the subset of patients on antiplatelet therapy (PRI: 72.8%±3.1% vs 61.7%±7.5%, p=0.071). Consistent findings were observed with all other platelet function tests. Patients with greater enhancement of inflammatory markers during AECOPD were more likely to present a higher increase in platelet reactivity. Conclusion: platelet reactivity is increased during AECOPD, which may contribute to the augmented cardiovascular risk of these patients. Additionally, the increase in platelet reactivity might be associated with an increment in inflammatory markers during exacerbations.
Note: Reproducció del document publicat a:
It is part of: International Journal of Chronic Obstructive Pulmonary Disease, 2017, vol. 2018, num. 13, p. 141-148
Related resource:
ISSN: 1176-9106
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
674349.pdf752.69 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons